Department of Surgery, University of Ulsan College of Medicine, 388-1 Pungnab2-dong, Songpa-gu, Seoul 138-736, Korea.
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
BACKGROUND/PURPOSE: Both curative resection and minimized in-hospital mortality offer the only chance of long-term survival in patients with hilar cholangiocarcinoma. The reported resectability rates for hilar cholangiocarcinoma have increased by virtue of combined major hepatectomy, but this procedure is technically demanding and still associated with a significant morbidity and mortality that must be carefully balanced against the chances of long-term survival.
Between January 2001 and December 2008, 350 patients with hilar cholangiocarcinoma underwent exploration for the purpose of potentially curative resection, of whom 302 (86.3%) were resected in the Department of Hepato-Biliary Surgery and Liver Transplantation, Asan Medical Center, University of Ulsan College of Medicine. Combined hepatectomy was carried out in 268 (88.7%) of 302 resected patients. Major hemihepatectomy and parenchyma-preserving hepatectomy were performed in 257 and 11 patients, respectively. Portal vein resection was associated in 40 (14.9%) of 268 hepatectomized patients. To control preoperative cholangitis and reduce risk of postoperative hepatic failure, biliary decompression through endoscopic and/or percutaneous transhepatic drainage and portal vein embolization were preoperatively applied in 329 (94.0%) of 350 explored patients and in 91 (54.2%) of 168 extended hepatectomized patients (154 right hemihepatectomy, 9 right trisectionectomy, 5 left trisectionectomy), respectively. Liver transplantation was not performed as primary treatment for hilar cholangiocarcinoma.
There were 5 cases (1.7%) of in-hospital death after resection and 1 postoperative liver failure that was successfully treated with liver transplantation. Major complications were encountered in 23 patients (7.0%), and the overall morbidity rate was 43%. In 302 resections, 214 (70.9%) were curative resections (R0) and 88 (29.1%) were palliative resections (R1). The overall 1-, 3- and 5-year survival rates after resection, including in-hospital deaths, were 84.6, 50.7 and 47.3% in the R0 group and 69.9, 33.3 and 7.5% in the R1 group, respectively. The 5-year survival rate of extended hemihepatectomy of 36.4% was better than that of parenchyma-preserving hepatectomy at 10.5%. Two significant predictive factors adversely affecting survival after resection were lymph node metastasis and incurability of surgery (P < 0.001). Two patients with vascular involvement who underwent concomitant hepatic artery and portal vein reconstruction are alive after more than 3 years.
Preoperative biliary decompression and portal vein embolization enabled us to reduce in-hospital deaths associated with extended hepatectomy for hilar cholangiocarcinoma. Major hemihepatectomy offers an increased survival because of the higher possibility of curative resection than bile duct resection alone and parenchyma-preserving hepatectomy, but it still carries a certain mortality. Less extensive procedures can be conducted safely and are beneficial for aged patients in poor condition with a less advanced tumor stage if tumor-free resectional margins are obtained.
背景/目的:根治性切除和降低院内死亡率均为肝门部胆管癌患者获得长期生存的唯一机会。由于联合进行大范围肝切除术,肝门部胆管癌的可切除率有所提高,但该手术技术要求高,仍然存在显著的发病率和死亡率,必须与长期生存的机会仔细平衡。
2001 年 1 月至 2008 年 12 月,350 例肝门部胆管癌患者接受了可能根治性切除的探查,其中 302 例(86.3%)在蔚山大学医学院峨山医学中心肝胆外科和肝移植科进行了切除。268 例(88.7%)切除患者进行了联合肝切除术。257 例患者进行了半肝切除术,11 例患者进行了保肝切除术。40 例(14.9%)肝切除患者合并门静脉切除。为了控制术前胆管炎和降低术后肝功能衰竭的风险,350 例探查患者中的 329 例(94.0%)和 168 例扩大肝切除患者中的 91 例(54.2%)接受了术前内镜和/或经皮经肝胆管引流和门静脉栓塞术(91 例中有 154 例为右半肝切除术,9 例为右三叶切除术,5 例为左三叶切除术)。肝移植未作为肝门部胆管癌的主要治疗方法。
切除术后院内死亡 5 例(1.7%),1 例术后肝功能衰竭经肝移植成功治疗。23 例(7.0%)发生重大并发症,总发病率为 43%。在 302 例切除术中,214 例(70.9%)为根治性切除(R0),88 例(29.1%)为姑息性切除(R1)。包括院内死亡在内,R0 组术后 1、3 和 5 年的生存率分别为 84.6%、50.7%和 47.3%,R1 组分别为 69.9%、33.3%和 7.5%。36.4%的扩大半肝切除术的 5 年生存率优于保肝切除术的 10.5%。有两个显著的预后不良因素影响术后生存:淋巴结转移和手术无法根治(P<0.001)。2 例伴有血管侵犯的患者同时进行肝动脉和门静脉重建,术后 3 年以上仍存活。
术前胆道减压和门静脉栓塞术使我们能够降低扩大肝切除术治疗肝门部胆管癌的院内死亡率。由于根治性切除的可能性高于单独胆管切除术和保肝切除术,因此进行大范围肝切除术可提高生存率,但仍存在一定的死亡率。如果能够获得无肿瘤残留的切缘,较小范围的手术可以安全进行,并有利于肿瘤分期较早、年龄较大且身体状况较差的患者。